A systematic review of long-acting β2-agonists versus higher doses of inhaled corticosteroids in asthma

Simple item page
dc.contributor.authorCastro Rodríguez, José Antonio
dc.contributor.authorRodrigo, Gustavo J.
dc.date.accessioned2021-12-06T12:26:05Z
dc.date.available2021-12-06T12:26:05Z
dc.date.issued2012
dc.description.abstractOBJECTIVE: To compare the efficacy of inhaled corticosteroids (ICS) plus long-acting β2 agonist (LABA) versus higher doses of ICS in children/adolescents with uncontrolled persistent asthma. METHODS: Randomized, prospective, controlled trials published January 1996 to January 2012 with a minimum of 4 weeks of LABA+ICS versus higher doses of ICS were retrieved through Medline, Embase, Central, and manufacturer’s databases. The primary outcome was asthma exacerbations requiring systemic corticosteroids; secondary outcomes were the pulmonary function test (PEF), withdrawals during the treatment period, days without symptoms, use of rescue medication, and adverse events. RESULTS: Nine studies (n = 1641 patients) met criteria for inclusion (7 compared LABA+ICS versus double ICS doses and 2 LABA+ICS versus higher than double ICS doses). There was no statistically significant difference in the number of patients with asthma exacerbations requiring systemic corticosteroids between children receiving LABA+ICS and those receiving higher doses of ICS (odds ratio = 0.76; 95% confidence interval: 0.48–1.22, P = .25, I2 = 16%). In the subgroup analysis, patients receiving LABA+ICS showed a decreased risk of asthma exacerbations compared with higher than twice ICS doses (odds ratio = 0.48; 95% confidence interval: 0.28–0.82, P = .007, I2= 0). Children treated with LABA+ICS had significantly higher PEF, less use of rescue medication, and higher short-term growth than those on higher ICS doses. There were no other significant differences in adverse events. CONCLUSIONS: There were no statistically significant group differences between ICS+LABA and double doses of ICS in reducing the incidence of asthma exacerbations but it did decrease the risk comparing to higher than double doses of ICS.
dc.fuente.origenORCID
dc.identifier.doi10.1542/peds.2012-0162
dc.identifier.eissn1098-4275
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-84865790306&partnerID=MN8TOARS
dc.identifier.urihttps://www.doi.org/10.1542/peds.2012-0162
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/63012
dc.information.autorucEscuela de medicina ; Castro Rodríguez, José Antonio ; 0000-0002-0708-4281 ; 113247
dc.issue.numeroNo. 3
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final657
dc.pagina.inicio650
dc.provenancengjara 2021-12-06 09:26:05
dc.relation.isformatofPediatrics, vol. 130, no.3, (sept. 2012), pp. 650-657.
dc.revistaPediatrics
dc.rightsacceso abierto
dc.subjectAsthma
dc.subjectChildren
dc.subjectAdolescents
dc.subjectLABA
dc.subjectInhaled corticosteroids
dc.subjectEfficacy
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.otherMedicina y salud
dc.titleA systematic review of long-acting β2-agonists versus higher doses of inhaled corticosteroids in asthma
dc.typeartículo
dc.volumenVol. 130
sipa.codpersvinculados113247
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
peds_2012-0162.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas